{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:15:46Z","timestamp":1791346546381,"version":"4.3.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Streptococcus pyogenes<\/jats:italic> (Spy)\u00a0Cas9 has potential as a\u00a0component of gene therapeutics for incurable diseases. One of its limitations is its large size, which impedes its formulation and delivery in therapeutic applications. Smaller Cas9s are an alternative, but\u00a0lack robust activity\u00a0or specificity and frequently recognize longer PAMs. Here, we investigated four uncharacterized, smaller Cas9s and found three employing a \u201cGG\u201d dinucleotide PAM similar to SpyCas9. Protein engineering generated synthetic RNA-guided nucleases (sRGNs) with editing efficiencies and specificities exceeding\u00a0even SpyCas9 in vitro and in human cell lines on disease-relevant targets. sRGN mRNA lipid nanoparticles displayed manufacturing advantages and high in vivo editing efficiency in the mouse liver. Finally, sRGNs, but not SpyCas9, could be packaged into all-in-one AAV particles with a gRNA and effected robust in vivo editing of non-human primate (NHP) retina photoreceptors. Human gene therapy efforts are expected to benefit from these improved alternatives to existing CRISPR\u00a0nucleases.<\/jats:p>","DOI":"10.1038\/s41467-021-24454-5","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T10:03:11Z","timestamp":1625824991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Improved CRISPR genome editing using small highly active and specific engineered RNA-guided nucleases"],"prefix":"10.1038","volume":"12","author":[{"given":"Moritz J.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christien","family":"Bednarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Gehrig-Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pitzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gamalinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Galonska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Dehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Lukason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Noma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Park-Windhol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacarmela","family":"Allocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albena","family":"Kantardzhieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Sane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Kosakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Cafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Tebbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Munzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Scaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Scharenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-3331","authenticated-orcid":false,"given":"Andr\u00e9","family":"Cohnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2551-2291","authenticated-orcid":false,"given":"Wayne M.","family":"Coco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"24454_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/495050a","volume":"495","author":"E Charpentier","year":"2013","unstructured":"Charpentier, E. & Doudna, J. A. Rewriting a genome. Nature 495, 50\u201351 (2013).","journal-title":"Nature"},{"key":"24454_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrmicro3569","volume":"13","author":"KS Makarova","year":"2015","unstructured":"Makarova, K. S. et al. An updated evolutionary classification of CRISPR-Cas systems. Nat. Rev. Microbiol 13, 722\u2013736 (2015).","journal-title":"Nat. Rev. Microbiol"},{"key":"24454_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"F Jiang","year":"2017","unstructured":"Jiang, F. & Doudna, J. A. CRISPR\u2013Cas9 structures and mechanisms. Annu. Rev. Biophys. 46, 505\u2013529 (2017).","journal-title":"Annu. Rev. Biophys."},{"key":"24454_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41579-019-0299-x","volume":"18","author":"KS Makarova","year":"2020","unstructured":"Makarova, K. S. et al. Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants. Nat. Rev. Microbiol 18, 67\u201383 (2020).","journal-title":"Nat. Rev. Microbiol"},{"key":"24454_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816\u2013821 (2012).","journal-title":"Science"},{"key":"24454_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823\u2013826 (2013).","journal-title":"Science"},{"key":"24454_CR7","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"24454_CR8","doi-asserted-by":"crossref","unstructured":"Hirakawa, M. P., Krishnakumar, R., Timlin, J. A., Carney, J. P. & Butler, K. S. Gene editing and CRISPR in the clinic: current and future perspectives. Biosci Rep 40, BSR20200127 (2020).","DOI":"10.1042\/BSR20200127"},{"key":"24454_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso, M. F., Tomkowicz, B., Perry, W. L. & Strohl, W. R. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 31, 317\u2013334 (2017).","journal-title":"BioDrugs"},{"key":"24454_CR10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","volume":"154","author":"LA Gilbert","year":"2013","unstructured":"Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in Eukaryotes. Cell 154, 442\u2013451 (2013).","journal-title":"Cell"},{"key":"24454_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nmeth.3312","volume":"12","author":"A Chavez","year":"2015","unstructured":"Chavez, A. et al. Highly efficient Cas9-mediated transcriptional programming. Nat. Methods 12, 326\u2013328 (2015).","journal-title":"Nat. Methods"},{"key":"24454_CR12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016).","journal-title":"Nature"},{"key":"24454_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"24454_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"24454_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines\u2014a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"24454_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"FA Ran","year":"2015","unstructured":"Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186\u2013191 (2015).","journal-title":"Nature"},{"key":"24454_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14500","volume":"8","author":"E Kim","year":"2017","unstructured":"Kim, E. et al. In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nat. Commun. 8, 14500 (2017).","journal-title":"Nat. Commun."},{"key":"24454_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04252-2","volume":"9","author":"M Adli","year":"2018","unstructured":"Adli, M. The CRISPR tool kit for genome editing and beyond. Nat. Commun. 9, 1911 (2018).","journal-title":"Nat. Commun."},{"key":"24454_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1783-3","volume":"20","author":"KC Keough","year":"2019","unstructured":"Keough, K. C. et al. AlleleAnalyzer: a tool for personalized and allele-specific sgRNA design. Genome Biol. 20, 167 (2019).","journal-title":"Genome Biol."},{"key":"24454_CR20","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1073\/pnas.78.5.2848","volume":"78","author":"M Streuli","year":"1981","unstructured":"Streuli, M. et al. Target cell specificity of two species of human interferon-alpha produced in Escherichia coli and of hybrid molecules derived from them. Proc. Natl Acad. Sci. USA 78, 2848\u20132852 (1981).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"24454_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/34663","volume":"391","author":"A Crameri","year":"1998","unstructured":"Crameri, A., Raillard, S.-A., Bermudez, E. & Stemmer, W. P. C. DNA shuffling of a family of genes from diverse species accelerates directed evolution. Nature 391, 288\u2013291 (1998).","journal-title":"Nature"},{"key":"24454_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/86744","volume":"19","author":"WM Coco","year":"2001","unstructured":"Coco, W. M. et al. DNA shuffling method for generating highly recombined genes and evolved enzymes. Nat. Biotechnol. 19, 354\u2013359 (2001).","journal-title":"Nat. Biotechnol."},{"key":"24454_CR23","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/nbt757","volume":"20","author":"WM Coco","year":"2002","unstructured":"Coco, W. M. et al. Growth factor engineering by degenerate homoduplex gene family recombination. Nat. Biotechnol. 20, 1246\u20131250 (2002).","journal-title":"Nat. Biotechnol."},{"key":"24454_CR24","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.molcel.2016.06.037","volume":"63","author":"M van Overbeek","year":"2016","unstructured":"van Overbeek, M. et al. DNA pepair profiling reveals nonrandom outcomes at Cas9-mediated breaks. Mol. Cell 63, 633\u2013646 (2016).","journal-title":"Mol. Cell"},{"key":"24454_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08224-4","volume":"10","author":"J Strecker","year":"2019","unstructured":"Strecker, J. et al. Engineering of CRISPR-Cas12b for human genome editing. Nat. Commun. 10, 212 (2019).","journal-title":"Nat. Commun."},{"key":"24454_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1261\/rna.067355.118","volume":"25","author":"P Yourik","year":"2019","unstructured":"Yourik, P., Fuchs, R. T., Mabuchi, M., Curcuru, J. L. & Robb, G. B. Staphylococcus aureus Cas9 is a multiple-turnover enzyme. RNA 25, 35\u201344 (2019).","journal-title":"RNA"},{"key":"24454_CR27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.2647","volume":"31","author":"PD Hsu","year":"2013","unstructured":"Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827\u2013832 (2013).","journal-title":"Nat. Biotechnol."},{"key":"24454_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","volume":"33","author":"SQ Tsai","year":"2015","unstructured":"Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187\u2013197 (2015).","journal-title":"Nat. Biotechnol."},{"key":"24454_CR29","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822\u2013826 (2013).","journal-title":"Nat. Biotechnol."},{"key":"24454_CR30","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1038\/mtna.2014.64","volume":"3","author":"TJ Cradick","year":"2014","unstructured":"Cradick, T. J., Qiu, P., Lee, C. M., Fine, E. J. & Bao, G. COSMID: a web-based tool for identifying and validating CRISPR\/Cas oOff-target sites. Mol. Ther. Nucleic Acids 3, e214 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"24454_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature24268","volume":"550","author":"JS Chen","year":"2017","unstructured":"Chen, J. S. et al. Enhanced proofreading governs CRISPR\u2013Cas9 targeting accuracy. Nature 550, 407\u2013410 (2017).","journal-title":"Nature"},{"key":"24454_CR32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","volume":"12","author":"S Vaidyanathan","year":"2018","unstructured":"Vaidyanathan, S. et al. Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol. Ther. Nucleic Acids 12, 530\u2013542 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"24454_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/humu.21634","volume":"33","author":"C Vach\u00e9","year":"2012","unstructured":"Vach\u00e9, C. et al. Usher syndrome type 2 caused by activation of an USH2A pseudoexon: implications for diagnosis and therapy. Hum. Mutat. 33, 104\u2013108 (2012).","journal-title":"Hum. Mutat."},{"key":"24454_CR34","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"CA Lino","year":"2018","unstructured":"Lino, C. A., Harper, J. C., Carney, J. P. & Timlin, J. A. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 25, 1234\u20131257 (2018).","journal-title":"Drug Deliv."},{"key":"24454_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/v11010028","volume":"11","author":"CL Xu","year":"2019","unstructured":"Xu, C. L., Ruan, M. Z. C., Mahajan, V. B. & Tsang, S. H. Viral delivery systems for CRISPR. Viruses 11, 28 (2019).","journal-title":"Viruses"},{"key":"24454_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13500-y","volume":"10","author":"RM Liu","year":"2019","unstructured":"Liu, R. M. et al. Synthetic chimeric nucleases function for efficient genome editing. Nat. Commun. 10, 5524 (2019).","journal-title":"Nat. Commun."},{"key":"24454_CR37","doi-asserted-by":"crossref","unstructured":"Hu, Z. et al. A compact Cas9 ortholog from Staphylococcus Auricularis (SauriCas9) expands the DNA targeting scope. PLoS Biol .18, e3000686 (2020).","DOI":"10.1371\/journal.pbio.3000686"},{"key":"24454_CR38","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/nbt.3404","volume":"33","author":"BP Kleinstiver","year":"2015","unstructured":"Kleinstiver, B. P. et al. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat. Biotechnol. 33, 1293\u20131298 (2015).","journal-title":"Nat. Biotechnol."},{"key":"24454_CR39","doi-asserted-by":"publisher","first-page":"eaaz4849","DOI":"10.1126\/sciadv.aaz4849","volume":"6","author":"C Saha","year":"2020","unstructured":"Saha, C. et al. Guide-free Cas9 from pathogenic Campylobacter jejuni bacteria causes severe damage to DNA. Sci. Adv. 6, eaaz4849 (2020).","journal-title":"Sci. Adv."},{"key":"24454_CR40","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.molcel.2018.12.003","volume":"73","author":"A Edraki","year":"2019","unstructured":"Edraki, A. et al. A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing. Mol. Cell 73, 714\u2013726 (2019). e4.","journal-title":"Mol. Cell"},{"key":"24454_CR41","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1126\/science.aav4294","volume":"362","author":"LB Harrington","year":"2018","unstructured":"Harrington, L. B. et al. Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. Science 362, 839\u2013842 (2018).","journal-title":"Science"},{"key":"24454_CR42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1126\/science.abb1400","volume":"369","author":"P Pausch","year":"2020","unstructured":"Pausch, P. et al. CRISPR-Cas\u03a6 from huge phages is a hypercompact genome editor. Science 369, 333\u2013337 (2020).","journal-title":"Science"},{"key":"24454_CR43","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt.2916","volume":"32","author":"C Kuscu","year":"2014","unstructured":"Kuscu, C., Arslan, S., Singh, R., Thorpe, J. & Adli, M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat. Biotechnol. 32, 677\u2013683 (2014).","journal-title":"Nat. Biotechnol."},{"key":"24454_CR44","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1093\/nar\/gku402","volume":"42","author":"Y Lin","year":"2014","unstructured":"Lin, Y. et al. CRISPR\/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res. 42, 7473\u20137485 (2014).","journal-title":"Nucleic Acids Res."},{"key":"24454_CR45","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements. Nat. Biotechnol. 36, 765\u2013771 (2018).","journal-title":"Nat. Biotechnol."},{"key":"24454_CR46","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.cell.2013.08.022","volume":"154","author":"H Yang","year":"2013","unstructured":"Yang, H. et al. One-step generation of mice carrying reporter and conditional alleles by CRISPR\/Cas-mediated genome engineering. Cell 154, 1370\u20131379 (2013).","journal-title":"Cell"},{"key":"24454_CR47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nmeth.3408","volume":"12","author":"V Iyer","year":"2015","unstructured":"Iyer, V. et al. Off-target mutations are rare in Cas9-modified mice. Nat. Methods 12, 479\u2013479 (2015).","journal-title":"Nat. Methods"},{"key":"24454_CR48","doi-asserted-by":"crossref","unstructured":"Iyer, V. et al. No unexpected CRISPR-Cas9 off-target activity revealed by trio sequencing of gene-edited mice. PLoS Genet. 14, e1007503 (2018).","DOI":"10.1371\/journal.pgen.1007503"},{"key":"24454_CR49","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell, S. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390, 849\u2013860 (2017).","journal-title":"Lancet"},{"key":"24454_CR50","doi-asserted-by":"publisher","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321 (2018). https:\/\/doi.org\/10.1056\/NEJMoa1716153.","DOI":"10.1056\/NEJMoa1716153."},{"key":"24454_CR51","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.2174\/1381612821666150531164540","volume":"21","author":"HY Xue","year":"2015","unstructured":"Xue, H. Y., Guo, P., Wen, W.-C. & Wong, H. L. Lipid-based nanocarriers for RNA delivery. Curr. Pharm. Des. 21, 3140\u20133147 (2015).","journal-title":"Curr. Pharm. Des."},{"key":"24454_CR52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","volume":"28","author":"T Beissert","year":"2020","unstructured":"Beissert, T. et al. A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol. Ther. 28, 119\u2013128 (2020).","journal-title":"Mol. Ther."},{"key":"24454_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2018","unstructured":"Colella, P., Ronzitti, G. & Mingozzi, F. Emerging issues in AAV-mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev. 8, 87\u2013104 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"24454_CR54","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature14592","volume":"523","author":"BP Kleinstiver","year":"2015","unstructured":"Kleinstiver, B. P. et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523, 481\u2013485 (2015).","journal-title":"Nature"},{"key":"24454_CR55","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.celrep.2017.12.041","volume":"22","author":"S Gong","year":"2018","unstructured":"Gong, S., Yu, H. H., Johnson, K. A. & Taylor, D. W. DNA unwinding is the primary determinant of CRISPR-Cas9 activity. Cell Rep. 22, 359\u2013371 (2018).","journal-title":"Cell Rep."},{"key":"24454_CR56","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.1648","volume":"8","author":"MT Certo","year":"2011","unstructured":"Certo, M. T. et al. Tracking genome engineering outcome at individual DNA breakpoints. Nat. Methods 8, 671\u2013676 (2011).","journal-title":"Nat. Methods"},{"key":"24454_CR57","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nbt.3583","volume":"34","author":"L Pinello","year":"2016","unstructured":"Pinello, L. et al. Analyzing CRISPR genome-editing experiments with CRISPResso. Nat. Biotechnol. 34, 695\u2013697 (2016).","journal-title":"Nat. Biotechnol."},{"key":"24454_CR58","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168\u2013e168 (2014).","journal-title":"Nucleic Acids Res."},{"key":"24454_CR59","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/nat.2017.0697","volume":"28","author":"JD Farelli","year":"2018","unstructured":"Farelli, J. D. et al. Leveraging rational protein engineering to improve mRNA therapeutics. Nucleic Acid Ther. 28, 74\u201385 (2018).","journal-title":"Nucleic Acid Ther."},{"key":"24454_CR60","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/gt.2010.56","volume":"17","author":"WA Beltran","year":"2010","unstructured":"Beltran, W. A. et al. rAAV2\/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promoters. Gene Ther. 17, 1162\u20131174 (2010).","journal-title":"Gene Ther."},{"key":"24454_CR61","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","volume":"25","author":"ML Maeder","year":"2019","unstructured":"Maeder, M. L. et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat. Med. 25, 229\u2013233 (2019).","journal-title":"Nat. Med."},{"key":"24454_CR62","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cell.2014.02.001","volume":"156","author":"H Nishimasu","year":"2014","unstructured":"Nishimasu, H. et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 156, 935\u2013949 (2014).","journal-title":"Cell"},{"key":"24454_CR63","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.cell.2015.08.007","volume":"162","author":"H Nishimasu","year":"2015","unstructured":"Nishimasu, H. et al. Crystal structure of Staphylococcus aureus Cas9. Cell 162, 1113\u20131126 (2015).","journal-title":"Cell"}],"updated-by":[{"DOI":"10.1038\/s41467-023-39141-w","type":"addendum","label":"Addendum","source":"publisher","updated":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24454-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24454-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24454-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T17:01:48Z","timestamp":1686675708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24454-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["24454"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-24454-5","relation":{"addendum":[{"id-type":"doi","id":"10.1038\/s41467-023-39141-w","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"15 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C., M.J.S., W.M.C., M.G., A.G., C.P., F.R., J.T., C.J.C., R.T., C.W.R., K.W., K.K., A.K., A.S., A.N., S.S. have filed patent applications through Bayer AG, Casebia LLC, and CRISPR Therapeutics on the results described herein. A.C., W.M.C., M.G., K.K., A.G., M.L., S.J.S., C.P., M.S., J.T. hold stock or shares in the affiliated companies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4219"}}